Skip to main content

Lumakras Side Effects

Generic name: sotorasib

Medically reviewed by Philip Thornton, DipPharm. Last updated on Oct 31, 2023.

Note: This document contains side effect information about sotorasib. Some dosage forms listed on this page may not apply to the brand name Lumakras.

Applies to sotorasib: oral tablet.

Serious side effects of Lumakras

Along with its needed effects, sotorasib (the active ingredient contained in Lumakras) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking sotorasib:

More common

Other side effects of Lumakras

Some side effects of sotorasib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to sotorasib: oral tablet.


The most common adverse reactions were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough; the most common laboratory abnormalities were decreased lymphocytes, decreased hemoglobin, increased AST, increased ALT, decreased calcium, increased alkaline phosphatase, increased urine protein, and decreased sodium. Serious adverse reactions occurred in 50% of patients treated with this drug and included pneumonia, hepatotoxicity, and diarrhea; the most common severe (Grade 3 or greater) adverse reactions were increased ALT, increased AST, and diarrhea. Fatal adverse reactions included respiratory failure, pneumonitis, cardiac arrest, cardiac failure, gastric ulcer, and pneumonia.

Permanent discontinuation of this drug due to an adverse reaction occurred in 9% of patients; adverse reactions leading to permanent discontinuation of therapy included hepatotoxicity, increased ALT, increased AST, and drug-induced liver injury.[Ref]


Very common (10% or more): Decreased lymphocytes (up to 48%), decreased hemoglobin (up to 43%), increased activated partial thromboplastin time (up to 23%), anemia[Ref]


Very common (10% or more): Diarrhea (up to 42%), nausea (up to 26%), vomiting (up to 17%), constipation (up to 16%), abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain; up to 15%)

Frequency not reported: Gastric ulcer[Ref]


Very common (10% or more): Increased AST (up to 39%), increased ALT (up to 38%), hepatotoxicity (included increased ALT, increased AST, increased blood bilirubin, drug-induced liver injury, hepatitis, hepatotoxicity, increased liver function test, increased transaminases; up to 25%)[Ref]

Among 357 patients who received this drug in a clinical trial, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). Among 359 patients who received this drug in a clinical trial, 17% had increased ALT/increased AST (Grade 3: 6%; Grade 4: 0.6%); the median time to first onset of increased ALT/AST was 8 to 9 weeks (range: 0.3 to 42 weeks). Increased ALT/AST leading to dose interruption or reduction occurred in 7% of patients; this drug was discontinued due to increased ALT/AST in 1.7% of patients. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.[Ref]


Very common (10% or more): Decreased calcium (up to 35%), increased alkaline phosphatase (up to 33%), decreased sodium (up to 28%), fatigue (included fatigue, asthenia; up to 26%), decreased albumin (up to 22%), edema (included generalized edema, localized edema, edema, peripheral edema, periorbital edema, testicular edema; up to 15%), pyrexia

Common (1% to 10%): Peripheral edema[Ref]


Very common (10% or more): Musculoskeletal pain (included back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, noncardiac chest pain, pain in extremity; up to 35%), arthralgia (up to 12%)[Ref]


Very common (10% or more): Increased urine protein (up to 29%)

Common (1% to 10%): Urinary tract infection[Ref]


Very common (10% or more): Cough (included cough, productive cough, upper airway cough syndrome; up to 20%), dyspnea (included dyspnea, exertional dyspnea; up to 16%), pneumonia (included pneumonia, aspiration pneumonia, bacterial pneumonia, staphylococcal pneumonia; up to 12%)

Frequency not reported: Respiratory failure, pneumonitis, interstitial lung disease (ILD)[Ref]

Among 359 patients who received this drug in a clinical trial, ILD/pneumonitis occurred in 0.8% of patients; all cases were Grade 3 or 4 at onset, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 2 weeks (range: 2 to 18 weeks). This drug was discontinued due to ILD/pneumonitis in 0.6% of patients.[Ref]


Common (1% to 10%): Hypertension

Frequency not reported: Cardiac arrest, cardiac failure


Very common (10% or more): Decreased appetite (up to 13%)

Common (1% to 10%): Hypokalemia, hyponatremia, hypocalcemia[Ref]


Very common (10% or more): Rash (included dermatitis, acneiform dermatitis, rash, maculopapular rash, pustular rash; up to 12%)[Ref]

Nervous system

Very common (10% or more): Headache

Frequently asked questions


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Lumakras (sotorasib). Amgen USA. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.